Solowin Holdings (NASDAQ: SWIN)

The QualityStocks Daily Newsletter would like to spotlight Solowin Holdings (NASDAQ: SWIN).

Solowin (NASDAQ: SWIN) , a financial services firm bridging traditional and digital assets, announced an initiative to reach US$1 billion in assets under management for its USD Money Market Real Yield Token (RYT) by the end of 2025. Launched April 15, 2025, through wholly owned subsidiary Solomon JFZ (Asia) Holdings Limited in collaboration with Standard Chartered, China Asset Management (Hong Kong), Libeara, and AlloyX, RYT offers institutional investors a compliant, yield-generating tokenized product with daily liquidity and multi-chain interoperability via partnerships with Polygon, Arbitrum, Solana, and Kucoin. Executives said the initiative reflects Hong Kong's drive to become a global hub for tokenized assets and Solowin's vision to deliver seamless Trad-Fi and Web3.0 financial services.

To view the full press release, visit https://ibn.fm/iK1R0

Solowin Holdings (NASDAQ: SWIN) is a versatile financial services provider focused on delivering comprehensive investment solutions from traditional finance as well as decentralized finance to high-net-worth and institutional clients. Operating through its wholly owned subsidiary, Solomon JFZ (Asia) Holdings Limited, Solowin is licensed by the Hong Kong Securities and Futures Commission and offers access to a full suite of financial services through its secure, one-stop electronic platform, Solomon Win.

Driven by a vision to create a modernized financial services infrastructure, especially to bridging traditional finance and the Web3 technology, Solowin has prioritized innovation, agility, and client-first experiences. The firm has experienced robust growth, aligning itself with evolving capital markets and emerging technologies. Its investment strategy is designed to enable seamless access to capital markets and diversified investment opportunities through cutting-edge financial technology.

Solowin is committed to building a global brand rooted in client success, regulatory compliance, and operational excellence. Its mission is to empower clients with flexible, integrated tools to grow and protect wealth in an increasingly complex financial landscape.

Portfolio

Solowin’s operations span five core verticals: securities brokerage, investment banking, asset management, virtual assets, and wealth management. Through its Solomon Win platform, the company provides individual and institutional clients with seamless access to financial markets around the world.

In investment banking, Solowin offers strategic advisory and capital formation services including IPO/SPAC listings, follow-on offerings, private placements, and debt financing. Its team assists issuers in aligning their business objectives with optimized listing strategies and investor targeting. Solowin also supports clients through financial advisory services such as mergers and acquisitions, business restructuring, and capital strategy development, alongside risk management and tax compliance services.

In wealth and asset management, Solowin delivers personalized financial planning via its securities brokerage and integrated investment solutions. Clients can access both in-house funds and top-tier international funds through the Solomon VA+ App, which also supports managed account services. On the frontier of fintech, Solowin offers Web3-based solutions such as virtual asset ETFs, cryptocurrencies, security token offerings, and tokenized real-world assets—positioning itself as a key player in the evolving digital finance space.

Market Opportunity

Solowin operates at the intersection of traditional finance and Web3 innovation, targeting a rapidly expanding global wealth management and fintech market. According to a report by Boston Consulting Group, global assets under management are projected to reach $147.4 trillion by 2027, up from $111.2 trillion in 2021, driven by increased demand for personalized and tech-enabled financial services. Additionally, the virtual asset market is poised for significant growth, with Boston Consulting Group forecasting that the tokenization of global illiquid assets could reach $16 trillion by 2030.

Hong Kong’s progressive stance on virtual assets has also positioned it as a regional hub for digital finance. Regulatory support from the Securities and Futures Commission has opened the door for regulated crypto trading platforms and tokenized asset solutions, which aligns with Solowin’s digital-first approach.

As wealth migrates toward hybrid portfolios combining traditional and virtual assets, Solowin is uniquely positioned to capitalize on both sectors.

Leadership Team

Peter Lok, Chief Executive Officer, an accomplished finance professional with extensive expertise in fund management, capital markets, and fundraising. His strategic insights in finance and capital allocation have been instrumental in driving capital growth.

Lily Liu, Chief Financial Officer, has more than a decade of experience in corporate finance, investment banking, and financial services. Her background includes IPOs, mergers and acquisitions, and private placements in both Hong Kong and U.S. capital markets, with a strong focus on risk management.

Ben Cheng, Chief Operating Officer, has 15+ years of operational expertise in securities brokerage and asset management. His specialties include regulatory compliance and Anti-Money Laundering/Counter-Financing of Terrorism (AML/CFT) oversight.

Solowin Holdings (NASDAQ: SWIN), closed Thursday's trading session at $4.49, up 5.3991%, on 319,429 volume. The average volume for the last 3 months is 515,397 and the stock's 52-week low/high is $1.16/$5.09.

Recent News

• Solowin Holdings (NASDAQ: SWIN) - ChineseNewsBreaks - Solowin Holdings (NASDAQ: SWIN) Targets $1 Billion AUM for Tokenized USD Money Market Product by Year-End 2025
• InvestorNewsBreaks - Solowin Holdings (NASDAQ: SWIN) Hits $100 Million in Transaction Volume for Licensed Coin-In/Coin-Out Services 
• An EV Pullback is Taking Shape in the US 

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

Soligenix (NASDAQ: SNGX) , a late-stage biopharma company developing treatments for rare diseases, reported Q2 2025 results and recent milestones. The company expects top-line Phase 2a results for SGX302 in mild-to-moderate psoriasis before year-end, along with continued updates from its investigator-initiated study of HyBryte(TM) for early-stage cutaneous T-cell lymphoma (CTCL). A confirmatory Phase 3 trial of HyBryte(TM) in early-stage CTCL is actively enrolling, with results anticipated in 2026. Soligenix also completed a Phase 2a proof-of-concept study of SGX945 for Behçet's Disease, achieving its primary objective of demonstrating biological efficacy, and transferred manufacturing of synthetic hypericin to the U.S. under its Sterling Pharma Solutions partnership. Q2 net loss widened to $2.7 million, or ($0.82) per share, from $1.6 million, with R&D expenses rising to $1.7 million on higher trial and manufacturing costs. Cash stood at $5.1 million on June 30, 2025, plus $1.4 million raised July 1, funding operations into Q1 2026.

To view the full press release, visit https://ibn.fm/SsFsy

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Thursday's trading session at $2.94, up 20%, on 794,294 volume. The average volume for the last 3 months is 17,816,685 and the stock's 52-week low/high is $1.09/$5.4.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - BioMedNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Q2 2025 Results Highlight Progress in Late-Stage Rare Disease Pipeline
• InvestorNewsBreaks - Alliance Global Partners Maintains Buy Rating, Increases Price Target as Soligenix Inc. (NASDAQ: SNGX) Advances Proprietary Clinical Programs
• BioMedNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Featured in NNW Editorial on Rare Disease Innovation

PowerBank Corporation (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN)

The QualityStocks Daily Newsletter would like to spotlight PowerBank Corporation (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN).

Vietnamese electric vehicle firm VinFast has advanced its entry into the Indian market via an agreement with BatX Energies, the largest lithium-ion battery recycling firm in India, to recycle electric vehicle batteries in the country. 

A recent report from Express Drives notes that the battery recycling company will be in charge of recycling high-voltage EV batteries, recovering reusable material, and repurposing them for secondary applications. The report comes weeks after VinFast paused its expansion into Western markets amidst significant competition, negative media attention, and numerous operational challenges. VinFast Asia CEO Pham Sanh Chau says the company's partnership with BatX Energies represents a notable step in its quest to build a circular and sustainable electric vehicle battery ecosystem in the Indian market. He notes that VinFast's vision of sustainability is about more than just building electric cars; it is about maintaining "environmental responsibility" through every stage of the lifecycle. Teaming up with BatX will help VinFast become more resource independent, bring it closer to achieving its national priorities, and set a standard for combining electric mobility with responsible innovation. It remains to be seen how successful the recycling effort started by VinFast in India will be, and whether this will result in viable input sources for affiliated verticals like battery makers, such a PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103). 

PowerBank Corporation (NASDAQ: SUUN) (CSE: SUNN) is a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the United States. The company is committed to advancing the transition to sustainable energy by offering end-to-end services that include project origination, financing structuring, engineering, procurement, construction, and long-term operations and maintenance. PowerBank focuses on delivering innovative energy solutions through solar photovoltaic systems, battery energy storage systems (BESS), and electric vehicle (EV) charging infrastructure.

With a vision to provide scalable and reliable clean energy solutions, PowerBank has established itself as a leader in the renewable energy market by cultivating partnerships with utilities, commercial and industrial entities, municipalities, and residential customers. Its vertically integrated business model allows for optimized efficiency, cost management, and returns across diverse markets in North America. This end-to-end approach ensures greater control over project quality, costs, and operational outcomes, strengthening its competitive position.

Driven by a mission to create a greener future, PowerBank manages a robust portfolio of projects, including more than 100 megawatts (MW) of developed capacity and a pipeline exceeding one gigawatt (GW). The company’s commitment to sustainability and innovation makes it a recognized player in the renewable energy sector.

PowerBank has offices in Toronto, Ontario and New York.

Projects

PowerBank boasts an impressive and diverse portfolio of renewable energy initiatives that underline its leadership in the clean energy space. In the U.S., the company has over 250 MW of solar projects under development, principally in New York, focusing on community solar farms and commercial and industrial installations. Notably, PowerBank is developing several community solar projects in upstate New York, which will deliver clean energy to local residents and small businesses. Community solar projects, which are a cornerstone of PowerBank’s portfolio, provide scalable solutions for renters, homeowners, and small businesses to access affordable renewable energy, driving localized energy independence and economic savings.

In Canada, PowerBank has been a significant participant in Ontario’s Feed-in-Tariff program, where it has secured contracts for close to 200 MW of capacity. Its current management includes 70 solar power projects, totaling 28.8 MW of operational solar assets. The company’s expertise extends to the development and ownership of battery energy storage systems and EV charging stations, further diversifying its portfolio.

The company’s vertically integrated approach spans the entire project lifecycle, from initial site acquisition and grid interconnection to long-term operation and maintenance services. This ensures seamless execution and high-quality outcomes, providing value to stakeholders and supporting the transition to a clean energy future.

Market Opportunity

PowerBank operates within a growing renewable energy market driven by global demand for sustainable power solutions. In North America, favorable policies such as the Inflation Reduction Act in the United States and Canada’s investments in green technologies provide a robust foundation for renewable energy adoption. Solar PV installations and battery energy storage systems are at the forefront of this expansion, addressing energy reliability and grid stability while reducing carbon emissions.

The North American solar PV market was valued at $25.02 billion in 2019 and is projected to reach $120.74 billion by 2027, growing at a compound annual growth rate (CAGR) of 21.7% from 2020 to 2027. Likewise, the global BESS market is expected to expand from $7.8 billion in 2024 to $25.6 billion by 2029, at a CAGR of 26.9%, as reported by MarketsandMarkets. These trends are driven by the increasing integration of renewable energy sources, the need for grid resilience, and declining technology costs.

PowerBank’s operations have it well-positioned to capitalize on these opportunities. With a development pipeline exceeding one gigawatt (GW), the company is focused on meeting growing demand in community and commercial solar sectors. Decentralized energy solutions, such as virtual net metering and behind-the-meter systems, further enhance PowerBank’s market potential by addressing the critical need for flexible, cost-effective, and sustainable energy infrastructure. By leveraging its vertically integrated model and diversified portfolio, PowerBank stands as a key player in driving the renewable energy transition.

Leadership Team

Dr. Richard Lu, MD, MSc., MHSc., MBA, serves as President and CEO of PowerBank, bringing over 25 years of global energy experience. His leadership has been instrumental in advancing the company’s strategic initiatives across North America, Europe, and Asia, with a focus on renewable energy development and operational excellence.

Sam Sun, MBA, is the Chief Financial Officer of PowerBank. A Chartered Professional Accountant with more than 15 years of expertise in corporate finance, Mr. Sun has overseen financial strategies and internal controls across the cleantech, manufacturing, and mining sectors in Canada, the U.S., and China.

Andrew van Doorn, PE, serves as Chief Operating Officer, with nearly three decades of experience in engineering and construction. Mr. van Doorn has successfully led projects totaling over 200 MW of solar capacity and is a former Chairman of the Canadian Solar Industries Association.

Tracy Zheng, MBA, Chief Development Officer, has over 25 years of experience in brand marketing, business development, and solar project operations. She has spearheaded sales initiatives, conducted feasibility studies, and negotiated key partnerships that drive PowerBank’s growth.

Matt Wayrynen, Executive Chairman and Director, has a background in resource company management, venture capital, and mergers and acquisitions. Under his leadership, Solar Flow-Through Funds, where Mr. Wayrynen acted as CEO, was acquired by PowerBank, enhancing its asset portfolio and growth prospects.

---

Forward Looking Statements

This report contains forward-looking statements and forward-looking information ‎within the meaning of Canadian securities legislation (collectively, “forward-looking ‎statements”) that relate to the Company’s current expectations and views of future events. ‎Any statements that express, or involve discussions as to, expectations, beliefs, plans, ‎objectives, assumptions or future events or performance (often, but not always, through the ‎use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will ‎continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, ‎‎”projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be ‎forward-looking statements and may involve estimates, assumptions and uncertainties ‎which could cause actual results or outcomes to differ materially from those expressed in ‎such forward-looking statements. In particular and without limitation, this report ‎contains forward-looking statements pertaining to the Company’s expectations regarding its industry trends and overall market growth of the data center market; the Company’s expansion into the data center market, including its pursuit of opportunities as a developer, owner, and strategic partner in data center infrastructure; supporting the demand for high-performance, sustainable energy solutions within the sector; details of the company’s business plan including development of solar power projects, battery storage projects and EV charging projects; the completion of any contracts for, or construction of, any data center, solar power, battery storage or EV projects; the receipt of interconnection approval, permits and financing to be able to construct projects; the receipt of incentives for projects; and the size of the Company’s development pipeline. No assurance ‎can be given that these expectations will prove to be correct and such forward-looking ‎statements included in this report should not be unduly relied upon. These ‎statements speak only as of the date of this report.‎

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. In making the forward looking statements included in this report, the Company has made various material assumptions, including but not limited to: obtaining the necessary regulatory approvals; that regulatory requirements will be maintained; general business and economic conditions; the Company’s ability to successfully execute its plans and intentions; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and services offered by the Company’s competitors; that the Company’s current good relationships with its service providers and other third parties will be maintained; and government subsidies and funding for renewable energy will continue as currently contemplated. Although the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and the Company cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements.

Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Forward-‎Looking Statements” and “Risk ‎Factors” in the Company’s most recently completed Annual Information Form, and other public filings of the Company, which include: the Company may be adversely affected by volatile solar power market and industry conditions; the execution of the Company’s growth strategy depends upon the continued availability of third-party financing arrangements; the Company’s future success depends partly on its ability to expand the pipeline of its energy business in several key markets; governments may revise, reduce or eliminate incentives and policy support schemes for solar and battery storage power; general global economic conditions may have an adverse impact on our operating performance and results of operations; the Company’s project development and construction activities may not be successful; developing and operating solar projects exposes the Company to various risks; the Company faces a number of risks involving Power Purchase Agreements (“PPAs”) and project-level financing arrangements; any changes to the laws, regulations and policies that the Company is subject to may present technical, regulatory and economic barriers to the purchase and use of solar power; the markets in which the Company competes are highly competitive and evolving quickly; an anti-circumvention investigation could adversely affect the Company by potentially raising the prices of key supplies for the construction of solar power projects; foreign exchange rate fluctuations; a change in the Company’s effective tax rate can have a significant adverse impact on its business; seasonal variations in demand linked to construction cycles and weather conditions may influence the Company’s results of operations; the Company may be unable to generate sufficient cash flows or have access to external financing; the Company may incur substantial additional indebtedness in the future; the Company is subject to risks from supply chain issues; risks related to inflation; unexpected warranty expenses that may not be adequately covered by the Company’s insurance policies; if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the renewable energy market; there are a limited number of purchasers of utility-scale quantities of electricity; compliance with environmental laws and regulations can be expensive; corporate responsibility may adversely impose additional costs; the future impact of any resurgence of COVID-19 on the Company is unknown at this time; the Company has limited insurance coverage; the Company will be reliant on information technology systems and may be subject to damaging cyberattacks; the Company may become subject to litigation; there is no guarantee on how the Company will use its available funds; the Company will continue to sell securities for cash to fund operations, capital expansion, mergers and acquisitions that will dilute the current shareholders; and future dilution as a result of financings.

The Company undertakes no obligation to update or revise any ‎forward-looking statements, whether as a result of new information, future events or ‎otherwise, except as may be required by law. New factors emerge from time to time, and it ‎is not possible for the Company to predict all of them, or assess the impact of each such ‎factor or the extent to which any factor, or combination of factors, may cause results to ‎differ materially from those contained in any forward-looking statement. Any forward-‎looking statements contained in this report are expressly qualified in their entirety by ‎this cautionary statement.‎

PowerBank Corporation (NASDAQ: SUUN), closed Thursday's trading session at $1.85, up 12.1212%, on 591,076 volume. The average volume for the last 3 months is 222,989 and the stock's 52-week low/high is $1.23/$6.43.

Recent News

• PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) - VinFast Signs Agreement to Recycle EV Batteries in India 
• EPA Terminates Biden-Era Solar Energy Program Worth $7bn 
• Experts Caution That the Environmental Impact of Renewable Energy Needs Scrutiny

Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF)

The QualityStocks Daily Newsletter would like to spotlight Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF).

The rise of AI has triggered an exponential growth in data-center construction and expansion, driving copper demand to unprecedented levels.

Bell Canada has announced the construction of six new AI data centers in British Columbia, including one in Merritt, British Columbia, strategically located near Nicola Mining.

The company recently provided updates on Craigmont exploration results, including drilling 14 holes with early findings revealing copper sulphide mineralization.

Copper's superior conductivity makes it a critical metal in the artificial intelligence ("AI") era, serving as the backbone of data-center infrastructure. Nicola Mining (TSX.V: NIM) (OTCQB: HUSIF) is positioning itself to meet escalating industrial demand through its New Craigmont Copper project, located in British Columbia, Canada.

Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) is a junior resource company focused on monetizing high-grade mineral assets in British Columbia. With a unique dual-pronged model, the company combines solid operational revenues from its wholly-owned, state-of-the-art gold and silver mill with the long-term upside of 100%-owned copper, silver, and gold exploration projects. This approach allows Nicola to fund ongoing development while minimizing equity dilution.

The company’s strategy centers on aligning infrastructure and permitting advantages with mineral-rich geology, positioning it to process its own, as well as third-party high-grade gold and silver mines via partnerships, to advance its own exploration targets. Key agreements with gold producers and concentrating sales contracts provide stable cash flow, making Nicola rare among juniors in its ability to internally support growth. Its solid balance sheet and business acumen have allowed it to take stakes in other near-term gold producers, including a 75% economic stake in Dominion Gold, which commences a bulk sample in 2H 2025.

Nicola is leveraging its platform of permitted infrastructure, strategic project locations, and deep technical expertise to build shareholder value in a low-risk, high-reward framework. The company is headquartered in Vancouver, British Columbia.

Projects

Nicola Mining’s project portfolio includes high-grade copper, silver, and gold assets located in mineral-rich regions of British Columbia. Each project is 100%-owned or majority-controlled, with strong exploration potential and the necessary permits to advance development.

New Craigmont Copper Project

Nicola’s flagship asset, the New Craigmont Project, is a historic producer of over 900 million pounds of copper. Since acquiring 100% ownership in 2015, the company has drilled over 18,000 meters and identified significant skarn-hosted and porphyry-style mineralization. Recent drilling in 2024 confirmed 52.9 meters at 1.03% Cu (Hole NC-24-002), supporting the presence of a large-scale copper system. The project benefits from paved road access, connection to BC Hydro’s grid, and proximity to urban centers.

Treasure Mountain Silver Project

This 100%-owned past-producing mine has a Major Mines permit (M-239) and an NI 43-101 compliant resource estimate. The site includes multiple silver-lead-zinc veins and is permitted to extract up to 60,000 tonnes annually. Nicola is evaluating potential reactivation or joint venture options. Resource estimates include indicated resources of 52,000 tonnes grading 18.1 oz/t Ag, 3.26% Pb, and 3.4% Zn, and inferred resources of 161,000 tonnes grading 22.0 oz/t Ag, 2.48% Pb, and 3.86% Zn.

Dominion Creek Project (Au-Ag)

Nicola holds a 50% land ownership and 75% economic stake in this gold-silver project. Located 43 km from Wells, British Columbia, the site has returned grab samples averaging 61.3 g/t Au and 173.7 g/t Ag. The company has received its final permit and plans to extract a 10,000-tonne bulk sample in 2025, which will be processed at its Merritt Mill facility.

Operations

In addition to its exploration assets, Nicola Mining operates a suite of permitted industrial facilities in British Columbia that generate revenue and support the company’s broader development strategy. These assets form the backbone of Nicola’s self-sustaining business model.

Merritt Mill & Tailings Facility

Nicola owns and operates British Columbia’s only provincially permitted toll mill for gold and silver, a $30 million flotation facility located near Merritt. Gold production began in 2023. The facility is supported by long-term Milling and Profit Share Agreements with companies including Osisko Development Corporation, Blue Lagoon Resources, and Talisker Resources.

Sand & Gravel Pit / Rock Quarry / Ready-Mix Concrete Plant

Nicola also operates a permitted gravel pit (100,000 t/year), rock quarry (1,500 t/day), and is set to launch a ready-mix cement plant in Q2 2025. These operations, run in partnership with local First Nations, generate stable cash flow to support exploration efforts.

Market Opportunity

Nicola Mining is uniquely positioned in southern British Columbia, a jurisdiction recognized for its mining-friendly policies, skilled labor force, and robust infrastructure. The New Craigmont Project is geologically situated within the Guichon Creek Batholith, a region hosting some of Canada’s largest copper mines, including Highland Valley. Exploration data from 2023 and 2024 support the potential presence of both skarn and porphyry systems, increasing the strategic value of Nicola’s holdings.

The company’s other assets, including Treasure Mountain and Dominion Creek, are located in historically productive areas with high-grade mineralization and established access routes. Dominion Creek, in particular, sits atop the Isaac Lake Fault system—identified in British Columbia’s RGS (Regional Geochemical Survey) as a highly anomalous gold-silver corridor. Nicola’s integrated production model enables it to generate revenue while advancing these exploration programs without excessive dilution, providing a distinct advantage in a volatile commodities market.

Leadership Team

Peter Espig, Chief Executive Officer & Director, is a former diamond driller who spearheaded Nicola through a restructuring into its recent growth. He brings over $2 billion in private equity transaction experience, is a pioneer of SPACs, and has held senior positions at Goldman Sachs Japan and Olympus Capital.

Will Whitty, VP of Exploration, brings to the company over 15 years of experience in copper and gold exploration. He previously worked at Freeport-McMoRan and Nevada Gold Mines. He holds a master’s degree from the Mineral Deposit Research Unit (MDRU) at the University of British Columbia.

Bill Cawker, Corporate Development, manages investor relations, communications, and corporate governance. He joined Nicola in 2023 and brings extensive small-cap public markets experience, along with a degree in economics from the University of British Columbia.

Sam Wong, Chief Financial Officer, is a CPA with over 18 years of experience in the mining sector. He previously held executive roles at several publicly listed resource companies. He began his career at Deloitte LLP in Vancouver.

Nicola Mining Inc. (OTCQB: HUSIF), closed Thursday's trading session at $0.60081, up 0.1850926%, on 9,075 volume. The average volume for the last 3 months is 86,990 and the stock's 52-week low/high is $0.1498/$0.642.

Recent News

• Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) - Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Advances New Craigmont Copper Project as AI Boom, Data-Center Surge Drives Copper Demand
• MiningNewsBreaks - Nicola Mining Inc. (TSX.V: NIM) (FSE: HLIA) (OTCQB: HUSIF) Begins 10,000-Tonne Bulk Sample at Dominion Creek Gold-Silver Project 
• Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Unlocks Value at Dominion Creek Gold-Silver Project

ONAR Holding Corp. (OTCQB: ONAR)

The QualityStocks Daily Newsletter would like to spotlight ONAR Holding Corp. (OTCQB: ONAR).

Multi-agent AI infrastructure partnership with IQSTEL addresses the fundamental challenge of isolated marketing data across platforms, creating unified intelligence for campaign optimization

Retina.ai acquisition brings customer lifetime value prediction and churn forecasting capabilities to ONAR's client roster, including brands like Unilever and Dollar Shave Club

Three-phase deployment strategy transforms agency operations from reactive optimization to proactive performance enhancement through interconnected AI agents

Marketing executives face a paradox that undermines billions in annual advertising investment. While artificial intelligence promises unprecedented campaign optimization capabilities, most marketing organizations operate with fragmented data ecosystems that render AI applications largely ineffective. Customer data sits isolated in CRM systems, campaign performance metrics remain trapped within platform dashboards, and creative insights exist in disconnected repositories across multiple tools. ONAR Holdings (OTCQB: ONAR) is addressing this market-wide challenge through a comprehensive approach that unifies marketing data across platforms, enabling AI systems to operate with complete visibility and deliver measurable performance improvements.

ONAR Holding Corp. (OTCQB: ONAR) is a leading marketing technology company and marketing agency network focused on delivering integrated, AI-driven solutions to accelerate revenue growth for its clients. Through an agile agency network specializing in performance marketing, full-service healthcare marketing, experiential marketing, and technology incubation, ONAR provides best-in-class services to a growing roster of clients worldwide.

Built on a foundation of innovation and operational excellence, ONAR’s vision is to redefine marketing services by leading with technological advancement. With employees across five continents, the company is aggressively expanding its team to support both organic growth and an active acquisition pipeline. ONAR’s strategic growth model focuses on growing and acquiring proven agencies under one umbrella to deliver superior service offerings across industries.

ONAR’s mission is to drive measurable client success through integrated, high-impact marketing solutions that blend creativity, data science, and technology. As it continues to expand, ONAR is focused on building a global marketing services network that serves companies ranging from $10 million to $300 million in revenue.

The company is headquartered in Miami, Florida.

Portfolio

ONAR’s operations are organized across a network of specialized agencies that together serve more than 45 clients across a wide range of industries. Each agency brings deep domain expertise and a results-driven approach:

• Storia: A premier performance marketing agency specializing in brand growth, paid media, and SEO. With a focus on data-driven excellence, Storia delivers highly targeted marketing strategies that maximize ROI across digital platforms. The agency partners with leading brands to drive measurable revenue outcomes and long-term brand equity.
• Of Kos: A full-service healthcare marketing agency committed to redefining the patient experience. Of Kos partners with healthcare professionals to deliver integrated campaigns that not only increase patient engagement but also elevate the standard of care across the healthcare landscape. Its work bridges marketing innovation and healthcare expertise to create real impact.
• CHALK: An experiential marketing agency that transforms bold ideas into unforgettable, immersive experiences. CHALK’s team of event architects specializes in designing events that break boundaries — from brand activations and pop-ups to major corporate experiences — creating lasting emotional connections between brands and audiences.
• ONAR Labs: The company’s pioneering technology incubator, ONAR Labs, brings together data scientists, engineers, and industry experts to develop proprietary marketing technologies. Every product is rigorously battle-tested within the agency network before commercialization, ensuring that ONAR Labs delivers real-world solutions that enhance marketing performance and client success.

Market Opportunity

ONAR operates at the intersection of marketing services and marketing technology, two sectors undergoing rapid evolution and expansion. The global digital marketing software market alone is projected to reach $264.15 billion by 2030, expanding at a CAGR of 19.4%, according to Grand View Research. Meanwhile, healthcare marketing and experiential marketing are experiencing renewed momentum, as companies seek to create more personalized and immersive customer experiences.

With its integrated, AI-driven platform and expertise across multiple high-growth verticals, ONAR is well positioned to capture a growing share of the marketing spend from mid-sized to large enterprise clients. As businesses increasingly prioritize digital transformation, customer experience, and data-driven marketing, ONAR’s diversified offerings and proprietary technologies through ONAR Labs create meaningful competitive advantages in a highly fragmented market.

Leadership Team

Claude Zdanow, Chief Executive Officer, is a seasoned entrepreneur and business leader with deep experience scaling service organizations and technology platforms. Prior to founding ONAR, he built and successfully exited multiple companies in marketing and media, combining creative vision with operational discipline to drive measurable client growth.

Chris Becker, President, brings extensive operational and strategic expertise to ONAR, focusing on driving agency performance and expanding the company’s integrated service offering. His leadership emphasizes operational rigor, client success, and scaling the company’s footprint across industries and regions.

Patricia Kaelin, Chief Financial Officer, oversees ONAR’s financial operations and strategic planning. A distinguished financial executive with more than 25 years of experience in scaling high-growth companies and leading finance teams at both public and private companies, she expertly manages financial strategy, M&A transactions, and provides a strong foundation for ONAR’s continued expansion and acquisition initiatives.

Sam Mendez, Chief of Staff, fosters seamless collaboration across the organization. She expertly manages strategic projects, facilitates clear communication channels, and acts as a key point of contact to maximize the executive team’s impact and advance organizational goals.

ONAR Holding Corp. (OTCQB: ONAR), closed Thursday's trading session at $0.0398, up 9.3407%, on 25,832 volume. The average volume for the last 3 months is 27,220 and the stock's 52-week low/high is $0.0238/$0.167.

Recent News

• ONAR Holding Corp. (OTCQB: ONAR) - ONAR Holdings Inc. (ONAR): Breaking Through Data Fragmentation Crisis
• TechMediaBreaks - Onar Holding Corporation (OTCQB: ONAR) Details Board Additions, AI Partnerships and M&A Moves
• ONAR Holding Corp. (ONAR) Expands AI Capabilities Through IQSTEL Partnership to Launch Multiagentic Infrastructure

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharma company developing novel treatments for primary and metastatic cancers in the brain and central nervous system, announced it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, taking place virtually Aug. 19–21, 2025.

To view the full press release, visit https://ibn.fm/EOCy9

It is easy to shrug off forgetfulness or a headache as stress. However, this isn't always the case as those symptoms could point to the possibility of a tumor in the brain. For women, this risk is even higher given that women make up 62.9% of people who develop noncancerous brain tumors. It is therefore important to know what to look out for, and which steps to take. First, it is important to know that when you are found to have a "benign" tumor in your brain, it doesn't mean that you are fine. The word benign is used as an alternative to noncancerous, but that doesn't mean those tumors are harmless. Early detection is vital, so keep your doctor informed about any changes you experience. Not every headache you have indicates that you have a brain tumor, but talking to your doctor will help in determining whether additional tests are needed to confirm what exactly is causing that headache. Currently, surgery to remove the benign tumor is the go-to treatment option, but some brain tumors are cancerous and often require a combination of surgery, radiation therapy or even chemotherapy. Many companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are working to bring to market more effective treatment options for brain tumors. The availability of those additional alternatives could improve the clinical outcomes of patients who aren't responding well to the existing treatments. 

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday's trading session at $6.03, off by 11.1929%, on 84,307 volume. The average volume for the last 3 months is 32,962 and the stock's 52-week low/high is $5.728/$221.94.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - What Women Need to Know About Benign Brain Tumors
• InvestorNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Webull Financial Biotech/MedTech Webinar Series
• Study Reveals Potential Way to Treat Pediatric Gliomas

Lantern Pharma Inc. (NASDAQ: LTRN)

The QualityStocks Daily Newsletter would like to spotlight Lantern Pharma Inc. (NASDAQ: LTRN).

Lantern Pharma (NASDAQ: LTRN) , a clinical-stage biopharma company leveraging its RADR(R) AI/ML platform for oncology drug discovery and development, announced Q2 2025 results and portfolio updates. The company reported complete responses in patients across two trials — LP-300 in advanced NSCLC and LP-284 in refractory diffuse large B-cell lymphoma — along with completion of LP-184 Phase 1a enrollment, positioning it for Phase 1b/2 studies in high-value indications. LP-184 has FDA Fast Track and multiple Rare Pediatric Disease designations and showed significant survival gains in ATRT models. Lantern strengthened its IP with a European patent allowance for LP-284 and publication of a PCT application for its predictBBB(TM) AI module. RADR(R) enhancements included the public launch of predictBBB.ai(TM) and a new drug combination prediction module. Q2 R&D expenses fell to $3.1 million from $3.9 million a year ago, G&A was $1.6 million versus $1.5 million, and net loss narrowed to $4.33 million from $4.96 million. Cash, equivalents, and marketable securities totaled $15.9 million at quarter-end, funding operations into June 2026.

To view the full press release, visit https://ibn.fm/VD5Ik

Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR® (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. The company has gained 11 FDA Designations for its portfolio of drug candidates including: Fast Track, Orphan and Pediatric Rare Disease. The company’s data-driven approach enables rapid identification of promising drug candidates and the design of targeted clinical trials for specific patient subpopulations and cancer types.

Lantern’s vision is to transform cancer treatment by integrating large-scale genomics, AI-based biomarker discovery, and preclinical modeling to accelerate the development of oncology drugs. The company’s pipeline includes three lead small molecule candidates and an antibody-drug conjugate (ADC) program across 12 cancer indications, supported by strategic collaborations with global research institutions and clinical partners. The company has three active clinical trials enrolling patients with multiple clinical milestones expected throughout the next twelve months.

The company’s mission is centered on transforming the cost and pace of developing innovative therapies for patients with genetically defined cancers or limited treatment options. Lantern is also advancing brain and CNS cancer drug development through its wholly owned subsidiary, Starlight Therapeutics.

The company is headquartered in Dallas, Texas.

Product Portfolio

Lantern Pharma’s product pipeline consists of three lead candidates—LP-300, LP-184, and LP-284—and a preclinical ADC program. All are guided by insights from the RADR® platform, which has grown to incorporate over 200 billion oncology-specific data points.

LP-300 is in a Phase 2 trial (Harmonic™) for non-small cell lung cancer (NSCLC) in never smokers. The trial evaluates LP-300 in combination with carboplatin and pemetrexed and has shown a clinical benefit rate of 86% and an objective response rate of 43% in its initial cohort. The study is enrolling 90 patients across the U.S., Japan, and Taiwan (NCT05456256).

LP-184 is in a Phase 1a trial for advanced solid tumors and GBM (NCT05933265). The compound has received FDA Fast Track Designations for GBM and triple-negative breast cancer (TNBC), as well as four Rare Pediatric Disease Designations. Upcoming Phase 1b/2 trials are planned for TNBC (monotherapy and with olaparib) and for NSCLC patients with KEAP1/STK11 mutations in combination with nivolumab and ipilimumab.

LP-284 is currently in a Phase 1 trial for relapsed or refractory non-Hodgkin’s lymphoma (NHL) and other solid tumors (NCT06132503). The drug candidate has demonstrated complete tumor suppression in preclinical models of mantle cell lymphoma resistant to Ibrutinib and bortezomib and showed synergistic activity with rituximab in high-grade B-cell lymphoma models.

Lantern’s ADC program is based on cryptophycin conjugates and is undergoing preclinical evaluation, showing sub-nanomolar potency and improved targeting in HER2-expressing models.

The company has also launched Starlight Therapeutics, focused on CNS cancers, where STAR-001 (LP-184 for CNS cancers) is advancing toward a Phase 1b/2 trial in glioblastoma and pediatric brain cancers, including ATRT, supported by Rare Pediatric Disease Designations and preclinical validation from Johns Hopkins.

Market Opportunity

Lantern Pharma is focused on oncology indications with significant unmet medical need and multi-billion-dollar commercial potential.

• LP-300 targets non-small cell lung cancer in never smokers, a patient population estimated at over 150,000 cases globally and representing a market opportunity exceeding $4 billion annually.
• LP-184 is positioned for use in DDR-deficient tumors such as pancreatic, bladder, and triple-negative breast cancers, which collectively represent a U.S. market opportunity estimated at over $10 billion annually. Opportunities in targeted DDR-deficient tumors include the KEAP1/STK11 mutant NSCLC population targeted by LP-184, with a market potential of over $2 billion annually, and TNBC, which alone represents a $4 billion global market given its aggressiveness and high brain metastasis rate.
• LP-284 is aimed at relapsed or refractory non-Hodgkin’s lymphomas, particularly mantle cell lymphoma and HGBL, within a market sized at $3.5 to $4 billion globally.
• CNS cancers addressed by Starlight Therapeutics further expand Lantern’s reach, representing an estimated $5 billion annual global opportunity, including both adult and pediatric cancers.

Leadership Team

Panna Sharma, President, Chief Executive Officer, and Director, leads Lantern Pharma with a deep background in oncology-focused biotechnology and artificial intelligence. He is responsible for Lantern’s strategic vision and has driven the growth of its AI-powered drug development platform. Prior to joining Lantern in 2018, he served as President and CEO of Cancer Genetics Inc. (NASDAQ: CGIX), where he raised over $100 million and expanded the company from 25 to over 250 employees across multiple continents. Earlier, he founded TSG Partners and played a key role in the IPO of iXL, a digital strategy firm.

David R. Margrave, Chief Financial Officer and Secretary, has served in executive roles in life sciences for over two decades. Before joining Lantern, he held leadership positions at BioNumerik Pharmaceuticals, including President and Chief Administrative Officer. He has also been a strategic consultant to multiple biotech firms and served as Senior Legal Advisor at MedCare Investment Corporation. Mr. Margrave holds a dual degree in Economics and Petroleum Engineering from Stanford University and a J.D. from The University of Texas School of Law.

Kishor G. Bhatia, Ph.D., Chief Scientific Officer, has more than 40 years of experience in cancer biology, including leadership at the National Cancer Institute where he served as Director of the AIDS Malignancy Program and held key roles in cancer treatment and diagnosis. He has also worked as an Adjunct Investigator and consultant to biotech firms such as Reprocell and Cancer Genetics. Dr. Bhatia earned his Ph.D. in Biochemistry from the University of Mumbai and completed postdoctoral research at Johns Hopkins University. He is a Fellow of the Royal College of Pathology in the UK.

Lantern Pharma Inc. (NASDAQ: LTRN), closed Thursday's trading session at $4.57, off by 3.9916%, on 162,383 volume. The average volume for the last 3 months is 357,273 and the stock's 52-week low/high is $2.55/$6.118.

Recent News

• Lantern Pharma Inc. (NASDAQ: LTRN) - AINewsBreaks - Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses in Multiple Trials, Expands AI Platform
• Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule
• Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN) , a late clinical-stage biopharma company developing treatments for neurodegenerative diseases, reported Q2 2025 results and said it has sufficient cash runway into Q1 2026. The company plans to meet with the FDA this quarter to review survival data for lead candidate CNM-Au8 in amyotrophic lateral sclerosis (ALS) and is preparing analyses of NIH-sponsored Expanded Access Program neurofilament light biomarker data, expected in Q4. These steps are intended to support a potential New Drug Application submission under the FDA's accelerated approval pathway for ALS by year-end 2025. Management said its focus remains on delivering an impactful therapy to the ALS community.

To view the full press release, visit https://ibn.fm/qTCmZ

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Thursday's trading session at $3.6, off by 1.3699%, on 65,133 volume. The average volume for the last 3 months is 68,076 and the stock's 52-week low/high is $2.2801/$6.9.

Recent News

• Clene Inc. (NASDAQ: CLNN) - BioMedNewsBreaks - Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results, Targets Year-End NDA Submission for ALS Therapy
• InvestorNewsBreaks - Clene Inc. (NASDAQ: CLNN) to Present Corporate Update at Emerging Growth Conference on Aug. 20 
• Parkinson's-Gut Bacteria Link Suggests Surprisingly Simple Treatment Option

Vision Marine Technologies Inc. (NASDAQ: VMAR)

The QualityStocks Daily Newsletter would like to spotlight Vision Marine Technologies Inc. (NASDAQ: VMAR).

Vision Marine Technologies (NASDAQ: VMAR) , a leader in premium on-water experiences and owner of Florida-based dealership network Nautical Ventures, announced Nautical Ventures has signed a Letter of Intent with Nimbus Boats USA to exclusively distribute Nimbus powerboats on Florida's West Coast. The agreement, expected to be finalized by March 31, 2026, would authorize Nautical Ventures to promote, sell and service Nimbus's Tender, Commuter, Weekender and Coupe series beginning August 1, 2025. The move aims to broaden Vision Marine's product portfolio, strengthen its Florida presence and capture demand in the fast-growing adventure-style boat segment. Florida remains the largest U.S. market for new powerboats, engines and accessories, generating $6.4 billion in 2023 sales. The Nimbus deal follows Vision Marine's June 2025 acquisition of Nautical Ventures, creating North America's first electric boat propulsion and multi-brand retail company.

To view the full press release, visit https://ibn.fm/tztnm

Vision Marine Technologies Inc. (NASDAQ: VMAR) is a global leader and innovator within the performance electric recreational boating industry. The company is engaged in designing and manufacturing electric outboard powertrain systems and related technology. It strives to be a guiding force for change and an ongoing driving factor in fighting the problems associated with waterway pollution by disrupting the traditional boating industry with electric power, in turn directly contributing to zero pollution, zero emission and a noiseless environment.

Vision Marine manufactures hand-crafted, highly durable, low maintenance, environmentally friendly electric recreational powerboats. The company’s business segments include the sale and rental of electric boats, with the majority of its revenue attributable to electric boat sales.

The designs and technology applied to Vision Marine’s boats result in enhanced performance, higher speeds and longer range. Put simply, Vision Marine boats offer a smoother ride than a traditional internal combustion engine motorboat.

The company is headquartered in Montreal.

Products

Vision Marine’s flagship E-Motion™ 180E electric marine powertrain is the first fully electric outboard powertrain combining advanced battery pack, inverter and high efficiency motor with proprietary union assembly between the transmission and motor. Vision Marine’s E-Motion and related technologies in this system utilize extensive control software and are uniquely designed to improve the efficiency of the outboard powertrain. As a result, both range and performance are enhanced.

More than a powerful electric outboard motor, the 180E is a complete powertrain package. The high-tech, marine-specific motor is equipped with multi-sensor captors and independent cooling, providing 180 horsepower.

An onboard charging system allows for quick and easy charging from any shore outlet, whether the vessel is in or out of the water. It implements cutting-edge marine battery packs that are IP67 certified and built to withstand the harshest marine environments. The system is glycol cooled with a controlled heat exchanger, ensuring optimal performance and longevity. A stainless-steel casing protects the battery from corrosion and physical damage over time.

The 180E is built to be integrated with many boat models produced by other marine manufacturers. Since boat manufacturers rarely build their own engines, instead choosing to source them from engine manufacturers, Vision Marine believes the 180E propulsion system can in the future end up powering nearly every recreational boat.

Market Opportunity

According to a report from Future Market Insights, a certified market research organization, the global electric boats market is expected to grow from a value of $5.6 billion in 2023 to $15.1 billion by 2033, achieving a CAGR of 10.4% during the forecast period.

Factors driving growth include rising seaborne commerce activities, a flourishing marine tourism industry and stringent emissions regulations aimed at reducing pollution. In addition, government support for electric speedboat adoption, advances in technological development and research and forecast expansion of needed charging infrastructure are credited as growth drivers.

An emphasis on reducing carbon emissions and encouraging consumer adoption of eco-friendly boats is also likely to drive expansion of the market, the report states.

Management Team

Alexandre Mongeon is Co-Founder and CEO of Vision Marine Technologies. He has served as CEO since 2014. Prior to that, he imported high-performance boats from the United States to Canada for more than 15 years. During much of that time, he also worked as a designer and contractor and managed several new construction projects on the waterfront in and around Montreal. He is a graduate of the School of Construction in Laval, Quebec, with a specialization in electrical systems.

Xavier Montagne is Chief Technical Officer at Vision Marine. Prior to joining the company, he was the CEO of Mac Engineering for six years. While there, he was the electric powerline architect of the Renault Trezor concept car (awarded 2016 Best Concept Car), technical designer of the Zoe E-sport race car driven in Formula-E races from 2016-2019 and senior battery designer for Forsee Power, SAFT, Renault and Peugeot in Europe, to mention a few of the many projects he headed. He received an electronic engineer diploma from IFITEP Paris Polytech in France.

Kulwant Sandher is CFO at Vision Marine. He is a Chartered Professional Accountant with more than 25 years of experience in business and finance. He has served as CFO of multiple public and private companies, including ElectraMeccanica Vehicles Corp., MineSense Technologies Inc., Alba Mineral Ltd., Delta Oil & Gas, Astorius Resources Ltd., Norsemont Mining Inc. and Intigold Mines Ltd. He graduated from Queen Mary College, University of London.

Vision Marine Technologies Inc. (NASDAQ: VMAR), closed Thursday's trading session at $2.84, off by 14.7147%, on 347,698 volume. The average volume for the last 3 months is 53,572 and the stock's 52-week low/high is $2.84/$658.665.

Recent News

• Vision Marine Technologies Inc. (NASDAQ: VMAR) - TechMediaBreaks - Vision Marine Technologies Inc. (NASDAQ: VMAR) Signs LOI for Exclusive Nimbus Boats Distribution on Florida's West Coast
• TechMediaBreaks - Vision Marine Technologies Inc. (NASDAQ: VMAR) Sees 504% Boat Sales Surge, Slashes Debt Following Nautical Ventures Acquisition 
• TechMediaBreaks - Vision Marine Technologies Inc. (NASDAQ: VMAR) Acquires Nautical Ventures to Launch First Integrated Electric Boat Dealership in North America

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

The Trump administration's price support strategy represents a significant shift in U.S. critical minerals policy.

Ucore Rare Metals' flagship RapidSX technology represents a breakthrough in rare earth element separation.

The strategic importance of Ucore's capabilities has attracted substantial government investment.

The Trump administration is developing a comprehensive strategy to strengthen the nation's critical minerals production and reduce Chinese market control through guaranteed minimum pricing for domestic rare earth producers, senior White House officials revealed ( https://ibn.fm/SdbJj ). Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) stands uniquely positioned to capitalize on this initiative through its revolutionary RapidSX(TM) technology, which addresses critical bottlenecks in rare earth element separation and processing.

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) s a critical metals technology company developing scalable rare earth element (“REE”) refining infrastructure in North America. Originally founded in 2006 as a mineral exploration company, Ucore has since evolved into a processing technology innovator focused on commercializing its proprietary RapidSX™ platform under a $18.4 million contract from the U.S. Department of Defense, with additional support from Natural Resources Canada. The company’s flagship deployment is the Louisiana Strategic Metals Complex (“SMC”), with additional SMCs planned to follow.

Ucore’s mission is to help reestablish a domestic REE supply chain by offering competitive, modular processing solutions that reduce dependence on China. Supported by government funding, private capital, and engineering partnerships, Ucore aims to meet growing demand for rare earth oxides in electric vehicles, defense systems, and advanced energy technologies.

The company is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Separation Technology

RapidSX™ is Ucore’s proprietary rare earth separation platform, delivering three times faster processing than traditional solvent extraction (SX) methods. Its current demonstration program in Kingston, Ontario, is being conducted under contract with the U.S. Department of Defense to prove commercial readiness for processing both heavy and light REEs. The project is also supported by Natural Resources Canada.

RapidSX™ employs a column-based design that eliminates the need for powered mixer-settlers, enabling a smaller facility footprint, quicker commissioning, and lower CAPEX and OPEX. The platform is adaptable to light and heavy REE feedstocks and is structured for modular scale-up.

The 52-stage RapidSX™ Commercial Demonstration Plant in Kingston, Ontario—operated in partnership with Kingston Process Metallurgy—has logged thousands of runtime hours and is currently processing rare earth feedstock further to the company’s U.S. Department of Defense contract. In January 2025, Ucore secured a $500,000 non-dilutive grant from Ontario’s Critical Minerals Innovation Fund to support the advancement of the Kingston facility and, in the words of Ontario Mines Minister George Pirie, “build a secure supply chain ready to fuel the technologies of tomorrow.”

Strategic Metals Complex – Louisiana

Ucore has selected an 80,800-square-foot brownfield site within the England Airpark in Alexandria, Louisiana, as the location for its first commercial rare earth refining facility. The Louisiana SMC is expected to scale from 2,000 tonnes per annum (TPA) of total rare earth oxides initially to 5,000 TPA, with potential to ultimately reach 7,500 TPA.

The facility benefits from Foreign Trade Zone (FTZ) status, reducing tariff burdens on imported inputs and enhancing logistics efficiency. In addition to these structural advantages, the state of Louisiana has outlined an incentive package valued at $15 million, including a $900,000 infrastructure grant and $360,000 in additional local support. The project is expected to create 100 family-wage jobs and has received strong support from federal and state officials.

To date, Ucore has secured $2.3 million in milestone payments under its $18.4 million OTA award from the U.S. Department of Defense. In early 2024, the company also secured C$2.16 million in private investment from Hondo Private Equity to support its commercialization efforts.

Bokan-Dotson Ridge REE Project – Alaska

Ucore maintains 100% ownership of the Bokan-Dotson Ridge heavy REE project in Southeast Alaska. A Preliminary Economic Assessment was completed in January 2013. The Alaska Industrial Development and Export Authority (AIDEA) has authorized $145 million in bond financing under SB99 (2014) to support future development.

While Bokan remains a long-term asset, Ucore continues to advance it at a measured pace, complementing its near-term focus on commercial rare earth refining and oxide production at the Louisiana SMC.

Market Opportunity

According to Grand View Research, the global rare earth elements market was estimated at $3.95 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030. The market outlook remains strong, fueled by the growing demand for permanent magnets and catalysts in the automotive sector.

In March 2025, President Trump invoked the Defense Production Act to prioritize domestic critical mineral production, signaling a national mandate to reduce reliance on “hostile foreign powers’ mineral production.” One month later, the Chinese government enacted immediate export restrictions on seven key rare earth elements, including dysprosium and terbium, further intensifying pressure on Western nations to develop secure and independent supply chains. This underscores the strategic value of Ucore’s domestic separation infrastructure.

Leadership Team

Pat Ryan, P.Eng., Chairman and CEO, is the founder of Neocon International, a leading automotive OEM supplier. He brings over 25 years of experience in global supply chain innovation and has led Ucore since 2014 in its strategic pivot toward rare earth processing.

Peter Manuel, Vice President, CFO & Corporate Secretary, has served as Ucore’s financial lead for 14 years. Trained as a Chartered Accountant, with extensive experience across Canada, England, and Ireland, Mr. Manuel has advised public and private entities on strategic planning, treasury, and assurance.

Michael Schrider, MEng, P.E., Vice President & COO, is a multidisciplinary engineer with over 30 years of experience. He founded and operated engineering firms SAi and ABD and has overseen all phases of Ucore’s technical development since 2016.

Geoff Atkins, Vice President of Business Development, has 30 years of mining experience and was instrumental in advancing both Lynas’ Mt. Weld and Vital Metals’ Nechalacho REE operations. He brings deep operational knowledge and leads feedstock strategy at Ucore.

Ucore Rare Metals Inc. (OTCQX: UURAF), closed Thursday's trading session at $2, off by 4.3062%, on 640,309 volume. The average volume for the last 3 months is 898,590 and the stock's 52-week low/high is $0.33/$2.2699.

Recent News

• Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) - Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Positioned to Benefit from Trump Administration Price Support for US Rare Earth Projects
• Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Secures $18.4M DoD Award to Fast-Track Heavy Rare Earth Independence
• Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Set to Leverage Proprietary Tech, New Trade Deals as Magnetic Materials Gatekeeper

Newton Golf Company Inc. (NASDAQ: NWTG)

The QualityStocks Daily Newsletter would like to spotlight Newton Golf Company Inc. (NASDAQ: NWTG).

Newton Golf Company (NASDAQ: NWTG) , a technology-forward golf company delivering physics-based performance innovations, reported Q2 2025 revenue of $2.1 million, up 154% from $813,000 in the year-ago quarter, with gross margin improving to 67.6% from 60.1%. First-half 2025 revenue rose 182% to $3.3 million, while net loss narrowed to $2.1 million from $2.4 million. The company cited rapid adoption of its new Fast Motion shaft—launched April 29—which generated more than $696,000 in gross sales in its first two months and has already surpassed 2,200 units sold in Q3. Additional highlights included surpassing 50 professional users across major tours, expanding global distribution, and increased direct-to-consumer sales. Management said rising demand, operational efficiency, and marketing investments position Newton Golf for continued growth in the second half of 2025.

To view the full press release, visit https://ibn.fm/nPv5u

Newton Golf Company Inc. (NASDAQ: NWTG), a Sacks Parente Company, is a technology-forward golf equipment manufacturer committed to enhancing player performance through innovative design. Since its founding in 2018, the company has developed a growing portfolio of premium golf products, including putters, golf shafts, grips, and related accessories. Its proprietary advancements include the First Vernier Acuity putter, patented Ultra-Low Balance Point (ULBP) technology, weight-forward Center-of-Gravity (CG) design, and ultra-light carbon fiber putter shafts.

As part of its commitment to growth in golf shaft technologies, the company expanded its manufacturing operations in April 2022, opening a dedicated facility in St. Joseph, Missouri. This move reinforced its goal of maintaining high-quality production standards while manufacturing and assembling substantially all of its products in the United States. In addition to golf clubs and accessories, Newton Golf Company is exploring expansion into golf apparel and other product categories.

The company sells its products through multiple channels, including resellers, its direct-to-consumer website, Club Champion retail stores, and distributors in the U.S., Japan, and South Korea. Future expansion may include growth through mergers, acquisitions, or the development of complementary product lines.

Newton Golf Company is headquartered in Camarillo, California.

Products

Newton Golf Company is focused on delivering high-performance golf equipment with a strong emphasis on precision engineering and cutting-edge materials. The company’s key product lines include:

• Newton Motion Golf Shafts: Launched in November 2023, these shafts are engineered with proprietary flex profiles designed for greater distance, reduced dispersion, and optimized performance across swing speeds. The company’s DOT system eliminates traditional shaft flex definitions, making it accessible to all golfers.
• Gravity Putters: Introduced in October 2024, these putters incorporate patented Ultra-Low Balance Point (ULBP) technology to improve stroke consistency and tighten putt dispersion. Manufactured in the U.S., they feature premium materials such as steel, aluminum, titanium alloys, and patented magnesium face plate technology.
• Golf Grips & Accessories: The company continues to innovate in this category, providing golfers with performance-enhancing grips and accessories to complement their clubs.

All Newton Golf Company products are manufactured with strict quality control standards to ensure precision and reliability, reinforcing the brand’s reputation for premium performance.

Market Opportunity

The global golf equipment market was valued at approximately $8 billion in 2022, with the U.S. market accounting for $2.9 billion. The golf club segment dominated the industry, representing 45.7% of total market share. Increasing participation in golf, particularly among younger players and women, is driving demand for high-quality, customizable golf equipment.

Key industry trends supporting growth include:

• The increasing popularity of premium, high-performance golf equipment among both professionals and amateurs.
• A shift toward customization, as golfers seek tailored products that enhance performance.
• A growing interest in golf from younger demographics, with amateur and collegiate golfers being particularly receptive to innovation.

Newton Golf Company’s emphasis on U.S.-based manufacturing provides it with a competitive edge in terms of supply chain efficiency, quality control, and sustainability, further strengthening its position in the market.

Leadership Team

Dr. Greg Campbell, Executive Chairman and Chief Executive Officer, brings nearly 40 years of experience in emerging technologies, product development, and public company leadership. He currently serves as CEO of V-Grid Energy Systems, a California-based company focused on converting agricultural waste into renewable electricity and bio-carbon. He has successfully taken two companies public and previously managed a $1.2 billion P&L as SVP & GM at Lam Research. Campbell holds a Ph.D. in Electrical and Electronics Engineering from UCLA and a BA/MA in Engineering from Cambridge University.

Ryan Stearns, Chief Financial Officer, was appointed in 2024 and oversees financial planning and corporate strategy. He brings expertise in scaling businesses and optimizing financial performance to support the company’s growth.

Newton Golf Company Inc. (NASDAQ: NWTG), closed Thursday's trading session at $1.8, off by 8.6294%, on 441,341 volume. The average volume for the last 3 months is 168,342 and the stock's 52-week low/high is $1.35/$119.1.

Recent News

• Newton Golf Company Inc. (NASDAQ: NWTG) - InvestorNewsBreaks - Newton Golf Company Inc. (NASDAQ: NWTG) Q2 2025 Revenue Jumps 154% on Strong Demand for Motion and Fast Motion Shafts 
• InvestorNewsBreaks - Newton Golf Company Inc. (NASDAQ: NWTG) to Host Webcast and Investor Q&A After Q2 2025 Results
• Newton Golf Company Inc. (NASDAQ: NWTG) Surpasses 50 PGA TOUR Professionals Using Its Shafts, Cementing Status as TOUR-Trusted Innovator

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT).

HeartBeam (NASDAQ: BEAT) , a medical technology company developing personalized cardiac care solutions, reported financial and operational results for the quarter ended June 30, 2025. The company said it remains on track to receive FDA 510(k) clearance for its 12-lead ECG synthesis software for arrhythmia assessment by year-end, following positive pivotal study results showing 93.4% diagnostic agreement with standard 12-lead ECGs. HeartBeam is executing commercial readiness plans, including establishing manufacturing, logistics, and cardiologist review services, with launch expected after clearance. Additional highlights include an accepted AI algorithm abstract for HRX Live 2025, issuance of a new international patent bringing the total to 21 worldwide, and multiple industry awards. Q2 R&D expenses rose to $3.3 million from $2.8 million a year ago, while G&A fell to $1.7 million from $2.2 million. Net loss was $5.0 million, flat year-over-year. Cash, equivalents, and short-term investments totaled $5.1 million at quarter-end.

To view the full press release, visit https://ibn.fm/qQm63

HeartBeam Inc. (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and monitoring of cardiac conditions. The company is creating the first ever cable-free synthesized 12-lead ECG platform designed to give patients the ability to record their symptoms the moment they occur, wherever they are. By providing synthesized, 12-lead ECG data, physicians can quickly assess the symptoms and ensure patients get the care they need in a timely manner. It also eliminates the need for wires, complex setup, or clinical staff, thus allowing synthesized 12-lead ECG signals to be accessible outside of a medical setting.

HeartBeam’s vision is to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside the confines of a traditional medical setting. Its patented approach not only delivers similar, but not identical, accuracy of conventional 12-lead ECGs for arrhythmia detection but also unlocks future capabilities in ischemia detection, AI-assisted analysis, and longitudinal cardiac trend tracking.

The HeartBeam System is now FDA cleared for arrhythmia assessment, following foundational 510(k) clearance granted in December 2024. The company submitted a 510(k) application for its 12-lead ECG synthesis software in January 2025 for arrhythmia assessment. As it approaches commercialization, HeartBeam is executing a multi-phase go-to-market strategy with initial U.S. rollout plans and a focus on high-margin, recurring revenue.

The company is headquartered in Santa Clara, California.

Products

HeartBeam’s flagship product is a credit card-sized, cable-free device designed to capture ECG signals in three non-coplanar directions and transform them into synthesized 12-lead ECGs. This novel form factor integrates a smartphone app, cloud connectivity, and a physician portal, enabling patients to record cardiac events at the moment symptoms occur and physicians to assess and triage in near real time.

The device is supported by an expanding software ecosystem. A key component of this is HeartBeam’s proprietary 12-lead ECG synthesis software, which met its clinical endpoint in the VALID-ECG pivotal study with 93.4% manual diagnostic agreement for arrhythmia assessment. This software is currently under FDA review and is designed to deliver clinical-grade arrhythmia diagnostic capabilities outside of traditional healthcare environments.

In April 2025, HeartBeam announced a strategic partnership with AccurKardia to incorporate its FDA-cleared ECG analysis software, AccurECG™, into HeartBeam’s offering. This integration is expected to enhance automated rhythm interpretation, streamline physician workflows, and improve diagnostic speed and accuracy.

Additional form factors are under development, including an on-demand synthesized 12-lead patch with issued patents, intended to serve the extended-wear market segment. These complementary offerings are intended to support chronic disease management and continuous monitoring applications, broadening HeartBeam’s total product ecosystem in the future.

Market Opportunity

HeartBeam is targeting large and growing segments within the $20 billion+ global cardiac monitoring and diagnostics market. According to the company’s own materials, the U.S. concierge care segment alone represents a $500 million serviceable addressable market (SAM), comprising approximately 1.5 million patients—500,000 of whom are at elevated cardiac risk. This initial focus provides a strategic entry point for cash-pay and early adoption.

Expanding beyond this niche, HeartBeam identifies a $1.3 billion to $2.6 billion annual opportunity in the broader U.S. direct patient pay market, driven by more than 2.6 million high-income individuals aged 35–74 with elevated cardiac risk. For comparison, more than 2.5 million Oura rings and over 3 million AliveCor Kardia devices have been sold, demonstrating strong consumer willingness to adopt personal cardiac technologies.

HeartBeam’s long-term opportunity is significantly larger. The company estimates that over 20 million people in the U.S. are at high risk for myocardial infarction (MI), representing a total addressable market nearly 40 times greater than the concierge segment. Additionally, the company’s on-demand 12-lead patch aims to capture market share in the extended wear and mobile cardiac telemetry (MCOT) space, competing with incumbents like iRhythm, Boston Scientific, Philips, and Baxter.

Leadership Team

Robert P. Eno, Chief Executive Officer and Director, brings over 30 years of experience launching disruptive medical technologies and leading commercialization efforts. He has held executive roles at HeartFlow, OptiMedica, NeoGuide Systems, and Avantec Vascular, and holds an MBA and BA from Stanford University.

Branislav Vajdic, PhD, President and Founder, is a seasoned innovator with over three decades of experience in technology and device development. He co-invented flash memory at Intel and led engineering teams responsible for the Pentium processor series. He previously served as CEO of NewCardio and holds a PhD in Electrical Engineering from the University of Minnesota.

Timothy Cruickshank, Chief Financial Officer, has over 15 years of experience in financial and strategic leadership roles. Formerly CFO at ImpediMed, he transformed the company into a SaaS-driven model. He holds an MBA from Keller Graduate School and a BS in Accounting from Syracuse University.

Peter J. Fitzgerald, MD, PhD, Chief Medical Officer, is a Stanford professor emeritus and interventional cardiologist with leadership in over 175 clinical trials and 24 medical startups. He co-founded TriVentures and has advised the FDA for over 20 years.

Ken Persen, Chief Technology Officer, has more than 25 years of experience in cardiac and digital health technology, including founding LIVMOR and leadership roles at Guidant and Cameron Health. He specializes in system design and product engineering for connected cardiac solutions.

HeartBeam Inc. (NASDAQ: BEAT), closed Thursday's trading session at $1.11, off by 7.5%, on 148,980 volume. The average volume for the last 3 months is 105,152 and the stock's 52-week low/high is $0.9101/$3.48.

Recent News

• HeartBeam Inc. (NASDAQ: BEAT) - BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Reports Q2 2025 Results, Advances Toward FDA Clearance and Commercial Launch
• HeartBeam Inc. (NASDAQ: BEAT) FDA-Cleared System Provides Momentum as Company Moves to Innovate Cardiac Care
• HeartBeam Inc.'s (NASDAQ: BEAT) Two New U.S. Patents Power Next Generation of Cardiac Diagnostics